Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1941 2
1942 1
1943 2
1944 2
1945 3
1946 7
1947 6
1948 4
1949 2
1950 4
1951 3
1952 5
1953 2
1954 9
1955 5
1956 5
1957 2
1958 3
1959 6
1960 6
1961 3
1962 1
1963 5
1964 10
1965 6
1966 4
1967 2
1968 1
1969 4
1970 3
1971 5
1972 5
1973 7
1974 7
1975 1
1976 3
1977 7
1978 3
1979 2
1980 2
1981 3
1982 3
1983 7
1984 3
1985 2
1986 1
1987 2
1988 4
1989 4
1990 6
1991 5
1992 5
1993 6
1994 3
1995 15
1996 8
1997 2
1998 8
1999 11
2000 8
2001 9
2002 13
2003 7
2004 5
2005 3
2006 3
2007 5
2008 8
2009 7
2010 9
2011 14
2012 9
2013 11
2014 18
2015 10
2016 7
2017 5
2018 5
2019 2
2020 5
2021 4
Text availability
Article attribute
Article type
Publication date

Search Results

408 results
Results by year
Filters applied: . Clear all
Page 1
PI3Kδ inhibition by idelalisib in patients with relapsed indolent lymphoma.
Gopal AK, Kahl BS, de Vos S, Wagner-Johnston ND, Schuster SJ, Jurczak WJ, Flinn IW, Flowers CR, Martin P, Viardot A, Blum KA, Goy AH, Davies AJ, Zinzani PL, Dreyling M, Johnson D, Miller LL, Holes L, Li D, Dansey RD, Godfrey WR, Salles GA. Gopal AK, et al. Among authors: miller ll. N Engl J Med. 2014 Mar 13;370(11):1008-18. doi: 10.1056/NEJMoa1314583. Epub 2014 Jan 22. N Engl J Med. 2014. PMID: 24450858 Free PMC article. Clinical Trial.
Idelalisib and rituximab in relapsed chronic lymphocytic leukemia.
Furman RR, Sharman JP, Coutre SE, Cheson BD, Pagel JM, Hillmen P, Barrientos JC, Zelenetz AD, Kipps TJ, Flinn I, Ghia P, Eradat H, Ervin T, Lamanna N, Coiffier B, Pettitt AR, Ma S, Stilgenbauer S, Cramer P, Aiello M, Johnson DM, Miller LL, Li D, Jahn TM, Dansey RD, Hallek M, O'Brien SM. Furman RR, et al. Among authors: miller ll. N Engl J Med. 2014 Mar 13;370(11):997-1007. doi: 10.1056/NEJMoa1315226. Epub 2014 Jan 22. N Engl J Med. 2014. PMID: 24450857 Free PMC article. Clinical Trial.
PTC124 targets genetic disorders caused by nonsense mutations.
Welch EM, Barton ER, Zhuo J, Tomizawa Y, Friesen WJ, Trifillis P, Paushkin S, Patel M, Trotta CR, Hwang S, Wilde RG, Karp G, Takasugi J, Chen G, Jones S, Ren H, Moon YC, Corson D, Turpoff AA, Campbell JA, Conn MM, Khan A, Almstead NG, Hedrick J, Mollin A, Risher N, Weetall M, Yeh S, Branstrom AA, Colacino JM, Babiak J, Ju WD, Hirawat S, Northcutt VJ, Miller LL, Spatrick P, He F, Kawana M, Feng H, Jacobson A, Peltz SW, Sweeney HL. Welch EM, et al. Among authors: miller ll. Nature. 2007 May 3;447(7140):87-91. doi: 10.1038/nature05756. Epub 2007 Apr 22. Nature. 2007. PMID: 17450125
Shade matching.
Miller LL. Miller LL. J Esthet Dent. 1993 Jul-Aug;5(4):143-53. doi: 10.1111/j.1708-8240.1993.tb00771.x. J Esthet Dent. 1993. PMID: 8037962 Review. No abstract available.
Alternative dosing schedules for irinotecan.
Rothenberg ML, Kuhn JG, Schaaf LJ, Drengler RL, Eckhardt SG, Villalona-Calero MA, Hammond L, Miller LL, Petit RG, Rowinsky EK, Von Hoff DD. Rothenberg ML, et al. Among authors: miller ll. Oncology (Williston Park). 1998 Aug;12(8 Suppl 6):68-71. Oncology (Williston Park). 1998. PMID: 9726095 Free article. Review.
408 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page